<DOC>
	<DOCNO>NCT02821858</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetics ( PK ) , safety tolerability follow single oral administration ascend dos odalasvir ( ODV ) healthy Japanese participant ( Panel 1 ) investigate PK , safety tolerability follow single oral administration ascend dos AL-335 healthy Japanese participant ( Panel 2 ; Sequential Design ) .</brief_summary>
	<brief_title>Study Investigate Pharmacokinetics , Safety Tolerability Odalasvir AL-335 Healthy Japanese Participants</brief_title>
	<detailed_description />
	<criteria>Participant must Japanese participant reside outside Japan 5 year whose parent grandparents Japanese determine participant 's verbal report Participant must body mass index ( BMI : weight kilogram [ kg ] divide square height meter ) 18.0 30.0 kilogram per meter square ( kg/m^2 ) , extremes include body weight le 50.0 kilogram ( kg ) Participant must healthy basis physical examination , medical history , vital sign , 12lead electrocardiogram ( ECG ) perform Screening . If abnormality , participant may include Investigator judge abnormality deviation normal clinically significant . This determination must record participant 's source document initial Investigator Participant must blood pressure ( participant supine 5 minute ) 90 140 millimeter mercury ( mmHg ) systolic , inclusive , high 90 mmHg diastolic . If blood pressure range , 2 repeat assessment permit Female participant must agree donate egg ( ovum , oocytes ) purpose assist reproduction study period 60 day ( Panel 1 ) 30 day ( Panel 2 ) study drug administration last followup visit , whichever occur later Participant history liver renal insufficiency ( estimate creatinine clearance 80 milliliter per minute [ mL/min ] ) ; significant cardiac , vascular , pulmonary , gastrointestinal ( significant diarrhea , gastric stasis , constipation Investigator 's opinion could influence drug absorption bioavailability ) , endocrine , neurologic , hematologic , rheumatologic , psychiatric , neoplastic metabolic disturbance Participant condition , opinion Investigator , participation would best interest participant ( example , compromise wellbeing ) could prevent , limit , confound protocolspecified assessment Participant past history heart arrhythmia ( example , extra systolic beat tachycardia rest ) ; risk factor associate Torsade de Pointes hypokalemia family history short/long QT syndrome sudden unexplained death ( include sudden infant death syndrome ) firstdegree relative [ example , sibling , offspring , biological parent ] ) Participant history clinically significant skin disease , limited , dermatitis , eczema , drug rash , psoriasis , food allergy , urticaria Participant known allergy , hypersensitivity , intolerance odalasvir ( ODV ) AL335 excipients</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>